VVZ 149

Drug Profile

VVZ 149

Alternative Names: VVZ-000149; VVZ-149

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vivozon
  • Class Analgesics
  • Mechanism of Action Glycine plasma membrane transport protein inhibitors; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Postoperative pain
  • Preclinical Pain; Pruritus

Most Recent Events

  • 01 Nov 2017 Vivozon initiates enrolment in a phase IIb trial for Postoperative pain in South Korea (IV) (NCT03347266)
  • 28 Apr 2017 Preclinical trials in Pain in USA (PO) (Vivozon pipeline, April 2017)
  • 28 Apr 2017 Preclinical trials in Pain in USA (Topical, Lotion) (Vivozon pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top